Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Wang, Zhijie; Wu, Lin; Li, Baolan; Cheng, Ying; Li, Xiaoling; Wang, Xicheng; Han, Liang; Wu, Xiaohong; Fan, Yun; Yu, Yan; Lv, Dongqing; Shi, Jianhua; Huang, Jianjin; Zhou, Shaozhang; Han, Baohui; Sun, Guogui; Guo, Qisen; Ji, Youxin; Zhu, Xiaoli; Hu, Sheng; Zhang, Wei; Wang, Qiming; Jia, Yuming; Wang, Ziping; Song, Yong; Wu, Jingxun; Shi, Meiqi; Li, Xingya; Han, Zhigang; Liu, Yunpeng; Yu, Zhuang; Liu, Anwen; Wang, Xiuwen; Zhou, Caicun; Zhong, Diansheng; Miao, Liyun; Zhang, Zhihong; Zhao, Hui; Yang, Jiaqi; Wang, Dong; Wang, Yingyi; Li, Qiang; Zhang, Xiaodong; Ji, Mei; Yang, Zhenzhou; Cui, Jiuwei; Gao, Beili; Wang, Buhai; Liu, Hu; Nie, Lei; He, Mei; Shi, Jin; Gu, Wei; Shu, Yongqian; Zhou, Tong; Feng, Jian; Yang, Xinmei; Huang, Cheng; Zhu, Bo; Yao, Yu; Tang, Xiongwen; Yu, Jianjun; Maher, Ellen; Feng, Hui; Yao, Sheng; Keegan, Patricia; Wang, Jie

doi:10.1200/jco.22.00727

Public

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Published in Journal of Clinical Oncology • Oct 7, 2022

Authors:

Zhijie Wang

Lin Wu

Baolan Li

Abstract

PURPOSE The CHOICE-01 study investigated the efficacy and safety of toripalimab in combination with chemotherapy as a first-line treatment for advanced non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS Patients (N = 465) with treatment-naive, advanced NSCLC without EGFR/ALK mutations were ran...

Subject

Medicine

Hazard ratio

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!